Voluntary Product Recall Initiated by Qualitest Pharmaceuticals Impacts Three Lots of Hydrocodone Bitartrate and Acetaminophen

Voluntary Product Recall Initiated by Qualitest Pharmaceuticals Impacts Three
  Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg
              Repackaged and Distributed by Mylan Institutional

PR Newswire

PITTSBURGH, Dec. 20, 2012

PITTSBURGH, Dec. 20, 2012 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that its Mylan Institutional business is conducting a voluntary
nationwide recall to the retail level of three lots of Hydrocodone Bitartrate
and Acetaminophen Tablets, USP 10 mg/500 mg (Lots 3037841, 3040859 and
3042573). The three lots were manufactured by Qualitest Pharmaceuticals, and
Mylan Institutional repackaged and distributed the product in unit dose
(CD100) under the UDL Laboratories, Inc. (n/k/a Mylan Institutional Inc.)
label. Qualitest Pharmaceuticals first initiated the recall on Dec. 6, 2012,
due to the possibility that a small number of tablets from the affected lots
may exceed the weight requirement and could exceed the label claim potency
requirements for the ingredients hydrocodone bitartrate and acetaminophen. As
indicated in Qualitest Pharmaceuticals' announcement, unintentional
administration of tablets with increased acetaminophen content could result in
liver toxicity, especially in patients on other acetaminophen containing
medications, patients with liver dysfunction, or people who consume more than
3 alcoholic beverages a day.

Additional information can be found at
http://www.fda.gov/Safety/Recalls/ucm331218.htm. Consumers who have the
affected lots can contactMylan Customer Service with questions at
800.848.0462 on Monday through Friday between 8 a.m. and 5 p.m. EST.

About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), +1-724-514-1968, Kris King (Investors),
+1-724-514-1813